Mereo BioPharma said on Monday that all three of its submitted abstracts have been accepted for presentation as posters at the American Thoracic Society meeting in Washington, 19-24 May 2017.
The abstracts submitted relate to Mereo’s clinical research with acumapimod (BCT-197), an orally active p38 MAP kinase inhibitor being developed as first-line acute therapy when added to standard of care for patients with an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).
Alastair MacKinnon, Mereo’s Chief Medical Officer, said: “We are extremely pleased to announce that all three of our submissions have been accepted for the high profile American Thoracic Society meeting in Washington. We are delighted that they have all been accepted and that the high quality of the research is being recognised by the American Thoracic Society. We look forward to attending the conference in May.”